Recently, the world’s first injectable ‘youthful appearance filler’ specifically designed for the temporal region (the temples) has received official approval from China’s National Medical Products Administration (NMPA). This novel biostimulatory dermal filler is primarily composed of poly-L-lactic acid (PLLA), which works by stimulating the body’s natural collagen production to restore facial volume and achieve a rejuvenated look—particularly addressing temple hollowing caused by aging.Unlike traditional hyaluronic acid fillers that provide immediate but temporary results, this ‘youthful appearance filler’ is a progressive, long-lasting regenerative agent. Its effects gradually appear over several weeks post-injection and can last between 18 to 24 months or longer. Key advantages include a natural appearance, durability, and a lower risk of complications such as migration or nodule formation. This approval marks a significant milestone, positioning China at the forefront of advanced regenerative aesthetic medicine globally.Experts note that the temples are a key ‘highlight zone’ of the face; their fullness significantly influences overall facial contour, youthfulness, and dimensionality. The launch of this product offers patients a safer, more natural anti-aging option, while also demanding higher technical precision—requiring administration by specially trained physicians to ensure optimal outcomes and safety.
近日，全球首款专用于颞部（太阳穴区域）的‘童颜针’——一种新型生物刺激型注射填充剂，正式获得国家药品监督管理局（NMPA）批准上市。这款产品主要成分为聚左旋乳酸（PLLA），通过刺激人体自身胶原蛋白再生，实现面部容积重建与年轻化效果，尤其针对因年龄增长导致的太阳穴凹陷问题。与传统玻尿酸等即时填充剂不同，‘童颜针’属于渐进式、长效型再生材料，效果通常在注射后数周逐渐显现，并可持续18至24个月甚至更久。其优势在于自然、持久，且不易产生移位或结节等并发症。此次获批标志着中国在高端医美再生材料领域迈入国际前沿。专家指出，颞部是面部‘高光区’之一，其饱满度直接影响整体轮廓的年轻感与立体感。该产品的上市为求美者提供了更安全、自然的抗衰新选择，同时也对医生操作技术提出更高要求，需由经过专业培训的医师进行精准注射以确保最佳效果与安全性。
原创文章，作者：admin，如若转载，请注明出处：https://avine.cn/15863.html